Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511351 | 0.92 | KDM4E (0.46) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL13690849 | 0.84 | PPARA (0.53) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL1549920 | 0.80 | IDO1 (0.40) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL4658500 | 0.80 | KDM4E (0.49) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL6283388 | 0.79 | MAPT (0.43) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL1691754 | 0.79 | KDM4E (0.53) | KDM4EKMT2APOLBTSHRALDH1A1 | |
| SCHEMBL16854417 | 0.78 | PPARA (0.53) | KDM4EMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1691112 | 0.78 | PTPRB (0.52) | KDM4EMEN1KMT2APOLBTSHR | |
| SCHEMBL23123287 | 0.78 | NPC1 (0.47) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL17709304 | 0.77 | ALDH1A1 (0.53) | KDM4EKMT2APOLBTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| US-10865186-B2 | Opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3074379-B1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS INDIA PVT LTD (IN) | 2019-06-26 | — | — | EP | disclosed |
| US-20180362468-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-12-20 | — | — | US | disclosed |
| US-10081602-B2 | Opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2018-09-25 | — | — | US | disclosed |
| US-20170253565-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2017-09-07 | — | — | US | disclosed |
| US-9688638-B2 | Opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170022167-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2017-01-26 | — | — | US | disclosed |
| EP-3074379-A1 | OPIOID AGONISTS AND USES THEREOF | Nektar Therapeutics (India) Pvt. Ltd. (IN) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015079459-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (INDIA) PVT.LTD. (IN) | 2015-06-04 | — | — | WO | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253565-A1 | OPIOID AGONISTS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | KDM4E 3977/4885MAPT 914/4885MEN1 4819/4885 |
| US-20170022167-A1 | OPIOID AGONISTS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | KDM4E 3977/4885MAPT 914/4885MEN1 4819/4885 |
| US-20180362468-A1 | OPIOID AGONISTS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | KDM4E 3977/4885MAPT 914/4885MEN1 4819/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | KDM4E 1129/4885MAPT 16/4885MEN1 586/4885 |
| US-10865186-B2 | Opioid agonists and uses thereof | OPRM1, OPRK1, OPRD1 | KDM4E 3977/4885MAPT 914/4885MEN1 4819/4885 |
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX5 | KDM4E 3924/4885MAPT 2176/4885MEN1 2887/4885 |
| US-10081602-B2 | Opioid agonists and uses thereof | OPRM1, OPRK1, OPRD1 | KDM4E 3977/4885MAPT 914/4885MEN1 4819/4885 |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX1, P2RX5 | KDM4E 3993/4885MAPT 2053/4885MEN1 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.